

Review



Cite this article: Alves I, Houle AA, Hussin JG, Awadalla P. 2017 The impact of recombination on human mutation load and disease.

Phil. Trans. R. Soc. B **372**: 20160465.

<http://dx.doi.org/10.1098/rstb.2016.0465>

Accepted: 3 August 2017

One contribution of 13 to a theme issue 'Evolutionary causes and consequences of recombination rate variation in sexual organisms'.

Subject Areas:

genomics, evolution

Keywords:

recombination, mutation load, cancer, disease, gene conversion, PRDM9

Author for correspondence:

Isabel Alves

e-mail: isabel.alves@oicr.on.ca

[†]These authors are joint first authors.

The impact of recombination on human mutation load and disease

Isabel Alves^{1,†}, Armande Ang Houle^{1,2,†}, Julie G. Hussin^{3,4}
and Philip Awadalla^{1,2}

¹Ontario Institute of Cancer Research, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3

²Department of Molecular Genetics, University of Toronto, Medical Science Building, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8

³Montreal Heart Institute, Department of Medicine, University of Montreal, 5000 Rue Bélanger, Montréal, Quebec, Canada H1T 1C8

⁴The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK

PA, 0000-0001-9946-6393

Recombination promotes genomic integrity among cells and tissues through double-strand break repair, and is critical for gamete formation and fertility through a strict regulation of the molecular mechanisms associated with proper chromosomal disjunction. In humans, congenital defects and recurrent structural abnormalities can be attributed to aberrant meiotic recombination. Moreover, mutations affecting genes involved in recombination pathways are directly linked to pathologies including infertility and cancer. Recombination is among the most prominent mechanism shaping genome variation, and is associated with not only the structuring of genomic variability, but is also tightly linked with the purging of deleterious mutations from populations. Together, these observations highlight the multiple roles of recombination in human genetics: its ability to act as a major force of evolution, its molecular potential to maintain genome repair and integrity in cell division and its mutagenic cost impacting disease evolution.

This article is part of the themed issue 'Evolutionary causes and consequences of recombination rate variation in sexual organisms'.

1. Introduction

Major advances in human population genetics in the past decade include the characterization of the primary genomic forces generating and shaping human variation: mutation [1–4] and recombination [5–11]. Recombination is a key mechanism shaping mutational variation across genomes and its impact is critical in evolutionary biology and human disease. Recombination can be simply defined as the process by which chromosomes exchange genetic material. In meiosis, new combinations of the parental genetic material are created to be transmitted to offspring. In mitosis, recombination-related processes ensure a conservative repair of double-strand breaks (DSBs) to minimize altered transmission of DNA to daughter cells.

From the early 1930s until the end of the 1970s, theoretical research [12–17] focused on models identifying conditions necessary for recombination (sexual reproduction) to evolve. In the 1980s, recombination was discovered to be critical in stabilizing homologous chromosomes and ensuring accurate chromosomal disjunction during meiosis in eukaryotes, as abnormal crossover frequencies were found to correlate with aneuploidy frequencies [18–20]. Additionally, recombination was found to be involved in the repair machinery of damaged DNA, which otherwise would accumulate lesions inflicted spontaneously or induced by the surrounding cell environment [21,22]. More recently, advances in statistical methods coupled with large collections of genomic variation have resulted in a better understanding of the distribution of recombination rates along the human genome and in the discovery that recombination frequencies are driven by genetic and epigenetic factors [5–11].

In this review, we focus on the impact of recombination on mutation accumulation and disease in humans by describing the interplay between molecular and

evolutionary mechanisms associated with the localization and regulation of meiotic and mitotic recombination. Specifically, we concentrate on the mechanisms underlying chromosome pairing and crossover establishment as well as on downstream pathways associated with DNA repair known to result in genomic disorders in the event of their disruption. We start by describing the association between recombination hotspots and its major regulator, PRDM9, as well as recent evidence for the role of PRDM9 in infertility and speciation. We also discuss the impact of dysregulated recombination-related pathways on fertility and how aberrant recombination affects structural genetic abnormalities, congenital defects and disease. We then examine the role of mitotic recombination on disease, particularly in cancer, by reviewing current evidence for the implication of homologous recombination mechanisms in DNA repair and tumorigenesis and finally, the potential of mitotic recombination as a mutagenic agent. To conclude, we present the current evidence for the impact of chromosomal linkage and GC-biased gene conversion on the accrual of deleterious mutations in human populations.

2. Meiotic recombination and infertility

Meiotic recombination is essential for accurate chromosomal disjunction and maintenance of genomic stability during meiosis in eukaryotes. During meiosis, the recombination process is initiated by the introduction of DSBs at specific locations across the genome, and their successful positioning, repair and resolution into crossovers depend upon many molecular processes that are essential to ensure genome integrity. Substantial variation in the rate and distribution of crossovers has been found within and among species, genders, populations and individuals. Within genomes, recombination rates and locations vary among chromosomes, at megabase and kilobase scales. In mammals, the distribution of crossovers along the genome is known to vary, and substantial regions of DNA with unusually low recombination are observed, known as coldspots, while highly localized peaks of recombination, known as hotspots, are also seen. In this section, we describe the evolutionary and molecular mechanisms of such variation in recombination rate and their implications for fertility in mammals.

(a) Meiotic recombination hotspots, PRDM9 and infertility

The first insights on the distribution of meiotic crossover events in humans emerged from the analysis of patterns of genetic inheritance among families focusing on a few specific regions of the genome [23,24]. Later, with genome-wide markers genotyped in families, genetic maps were constructed first at the megabase scale [25,26] and later at higher resolution [4,7,8,27]. High-resolution recombination maps revealed the presence of heterogeneous rates of recombination across the genome and sex-specific genetic map lengths [27,28], whereas molecular characterization of recombination events through single and pooled sperm genotyping led to the identification and characterization of individual hotspots [29–31]. With sperm genotyping, such areas were shown to correspond to clusters of recombination breakpoints spanning 1–2 kb [29].

Linkage disequilibrium (LD), the non-random association of alleles among different loci, is mainly driven by local rates of recombination: the smaller the rate, the higher the

covariation of alleles between loci. As distance between pairs of polymorphic sites increases, the probability of a recombination event occurring between them increases, and covariation is reduced. Across the human genome, LD can be mainly described by large blocks of close associations that are intermittently broken [30,32]. Population genetic-based statistical methods [7,33–37] exploiting distributions of associations allow for the characterization of recombination rate variation at relatively fine resolution. For instance, LD-based analyses confirmed that meiotic crossovers are non-randomly distributed in the human genome, with the largest number of them occurring only in 10% of the genome and preferentially not within genes [7]. Furthermore, LD-based methods led to the identification of thousands of recombination hotspots genome-wide, whose location is associated with the distribution of a degenerate 13-mer sequence motif [8,38] crucial in recruiting crossover activity in at least 40% of the human recombination hotspots, regardless of the population ancestry background and sex, and associated with genomic instability and disease-causing breakpoints [38]. The 13-mer motif was inferred to be the binding site of a zinc-finger (ZnF) protein [38]—the PR domain-containing 9 (PRDM9), a histone methyltransferase [9–11]. Molecular experiments and bioinformatics analyses confirmed the binding affinity of multiple PRDM9 ZnF alleles to specific motifs including the previously identified degenerate hotspot motif [9]. Polymorphisms in the ZnF domain of PRDM9 were shown to be associated with alternative sequence motifs and underlie differences in the location of hotspots in human populations [39]. The epigenetic modification H3K4me3 (the tri-methylation of histone H3 on lysine 4) has been reported to mark the activity of meiotic recombination hotspots [40], and recent studies in mice [41] and human cell lines [42] have also associated recombination initiation sites with the H3K36me3 (the tri-methylation of histone H3 on lysine 36) mark. Interestingly, PRDM9 was found to catalyse both of these epigenetic marks [41–43]. Together, these findings indicate that the binding sites of PRDM9 specify the genome-wide location of hotspots and control the distribution of recombination events, probably by promoting recombination initiation through DSBs [44].

In chimpanzees, the PRDM9 homologue does not recognize the human PRDM9 13-mer sequence binding motif, while appearing to bind to different sequence motifs [10]. Furthermore, the PRDM9 ZnF array appears to have diverged more from the human counterpart than any other homologous ZnF protein [10]. These observations are consistent with the hypothesis that recombination hotspot locations are evolving at a rapid rate [8,45,46], explaining the differences in recombination hotspot distributions between humans and chimpanzees [47–50] and differences between current (sperm genotyping) and historical (LD-based) hotspot locations [29,45,51]. The rapid evolution of PRDM9 may be driven by the quick turnover of DNA motifs at sites of recombination [10]. During DSB repair at heterozygous sites, the homologous chromosome containing the non-recombinogenic allele will be used to repair the broken DNA sequence, a mechanism known as gene conversion, and will drive the extinction of the PRDM9 binding motif [51,52]. As the extinction of hotspots challenges requirements for proper chromosomal segregation in meiosis, new PRDM9 variants may emerge that are able to recognize new motifs and thus ensure the proper functioning of recombination. PRDM9 includes a ZnF minisatellite-like structure vulnerable to sequence rearrangements during DNA

replication and likely to explain high levels of polymorphism of the *PRDM9* ZnF array [10]. Additionally, single-nucleotide polymorphisms within *PRDM9* concentrate at the DNA-binding amino acids of the array not only in humans but also in primates and rodents [53]. Together, the evidence suggests that high mutation rate and positive selection may jointly contribute to fast rates of evolution at *PRDM9*. A ‘Red-Queen’ dynamic has been proposed to model the motif erosion, via biased gene conversion, and the fast generation of new forms of *PRDM9* to recognize new binding sites and thus maintain chromosomal crossover rates has been suggested to follow [46,54–57]. Under such a model of evolution, the 13-mer sequence motif, the current target of the most common human allele, might be condemned to extinction in the next 3 million years [55]. Interestingly, while *PRDM9* plays a unique role in rapidly changing the location of recombination hotspots in primates and rodents, taxonomic groups lacking *PRDM9* homologues appear to have conserved stable recombination landscapes [46,58,59].

Importantly, *PRDM9* has been implicated in infertility due to abnormal placement of meiotic DSBs and early pachytene arrest and is the first (and only) ‘speciation’ gene to be described in vertebrates. Although *PRDM9* knockouts in mice cause sterility in both sexes [43], allelic incompatibility between *Mus musculus musculus* and *Mus musculus domesticus* [60] causes hybrid sterility only in males. Recent findings have established the connection between hybrid male sterility, allelic variation at *PRDM9* and chromosomal asynapsis during meiosis [61–63]. A compelling model for the mechanistic basis of hybrid sterility and chromosomal asynapsis was proposed, based on analyses of DSB maps in transgenic mice [63]. The erosion of *PRDM9* motifs leads to asymmetric *PRDM9* binding in hybrids, which is associated with high asynapsis rates in pachytene and downregulation of autosomal genes [64], potentially leading to major meiotic defects and sterility. It is therefore plausible that these newly discovered mechanisms affect levels of hybrid fertility in other mammalian species with *PRDM9*, and possibly play a broader role in speciation.

(b) Meiosis, recombination and infertility

Meiosis is a complex developmental process of two cell divisions, transforming one diploid cell into four haploid cells. The first division (meiosis I) is characterized by an extended prophase, which includes steps governing the movement and organization of meiotic chromosomes. Our understanding of the genetic control of meiosis comes from different experimental systems [65], with genomic and functional information defining a ‘core meiotic recombination machinery’ that exhibits strong conservation across eukaryotes [66]. Successful meiosis completion depends upon proper positioning of crossover events between paired homologues that provide temporary connections between homologues, called chiasmata. Chiasma formation is well described by the Szostak model [67], which predicts that the central intermediate of crossover formation is a four-way DNA junction structure, known as double Holliday junction, that physically connects the two recombining DNA molecules and allows them to orient and segregate towards opposite poles of the spindle in metaphase I [68]. The synaptonemal complex spans the gap between paired chromosomes during meiosis and may regulate chromosome-wide crossover distribution [69]. Errors in meiotic

recombination are often a source of harmful mutations, aberrant chromosomes and defective gametes, with important clinical consequences.

Severe genetic defects in prophase I key players generally lead to infertility owing to gametocyte apoptosis. For instance, in mice, null alleles in genes involved in chromosome synapsis (e.g. *SMC1*, *REC8*, *SYCP2* and *SYCP3*) and DSB repair result in elevated aneuploidy rates by meiotic arrest, highly reduced fertility or even infertility [70–74]. Also in mice, sensitivity to meiotic disruption is often sexually dimorphic. Some genetic defects affecting prophase I progression will lead to sterile males as a result of apoptosis of spermatocytes, whereas females remain fully fertile or subfertile (e.g. *FKBP6*, *PRDM9*). In other cases, meiotic progression stops at different stages in females and males, revealing distinct molecular functions of key meiotic players, or altered checkpoints on recombination-linked phenotypes in the two sexes (*SPO11*, *RAD51C*) [75,76]. Whether the sexually dimorphic nature of meiotic genes involved in both recombination and infertility is recapitulated in humans is unclear, but important sex differences in recombination rates are widely established [27,28,77–79]. For instance, genome-wide crossover rates in humans correlate with polymorphisms in *RNF212* [80], with haplotypes increasing recombination rate in one sex associated with reduced recombination rate in the other [81].

In humans, infertility is a relatively common problem but infertility-causing mutations in meiotic genes have remained largely elusive, with the exception of *SPO11*, *SYCP3*, *PRDM9* and *CDK2* mutations [82–86]. Even when novel associations are reported, the identification of causative polymorphisms and mechanisms remains problematic. However, a CRISPR/Cas9 genome editing strategy has been successful in modelling putatively deleterious variants in mouse orthologues of human fertility genes [85]. Alternatively, generating primordial germ cells using induced pluripotent stem cells from infertile patients is likely to provide valuable *in vitro* genetic models to improve our understanding of meiotic mechanisms causing infertility in humans [87].

3. Meiotic and mitotic genomic disorders

(a) Aberrant recombination promotes genomic instability

In humans, altered meiotic recombination is associated with large structural rearrangements, aneuploidies and infertility. These instabilities are mostly caused by disturbances at different steps of the molecular process as briefly summarized in table 1. Indeed, altered meiotic recombination is the first correlate associated with abnormal chromosome segregation occurring in at least 5% of clinically recognized human pregnancies, making aneuploidy the leading cause of pregnancy loss [88]. More than 20% of human oocytes are estimated to be aneuploid, compared to only 2% of spermatocytes [88] even though human males have lower recombination rates, highlighting a dramatic difference between female and male regulation of chromosome segregation. The molecular factors of this sexually dimorphic error-prone process remain largely unknown, except for disturbances in crossover pathways, which are associated with non-disjunction. In humans, a significant reduction in the number of crossover events is a feature of all trisomies studied [88] and suboptimally

Table 1. Diseases associated with dysfunctional recombination mechanisms.

recombination mechanism implicated	type of disorder
chromosome synapsis and recombination initiation	infertility [71,72,74]
maintenance of physical connections between chromosomes	aneuploidies [88]: trisomy 13, 15, 16, 18, 21
Holliday junction resolution	mosaic variegated aneuploidy
non-allelic homologous recombination	genomic disorders [89]: (e.g. Charcot–Marie–Tooth disease type 1A, neurofibromatosis type 1, Williams–Beuren syndrome, Smith–Magenis syndrome, hereditary neuropathy with liability to pressure palsies, DiGeorge syndrome, Prader–Willi syndrome, childhood spinal muscular atrophy, 17q21.31 microdel syndrome, etc.)
mitotic non-allelic homologous recombination	autism, 8p23.1 deletion, 16p11.2 deletion, 17q11.2 deletion [90], neurofibromin-1 [91]
Holliday junction resolution	Fanconi anaemia [92], squamous cell carcinomas [93]
illegitimate immunoglobulin recombination	severe combined immunodeficiencies [94]
recognition of double-strand breaks	ataxia telangiectasia [95] Nijmegen's breakage syndrome [96]
excessive homologous recombination	Bloom syndrome [97]
DNA repair by homologous recombination	cancers [98]
acquired chromosomal translocations	
chromoplexis, chromothripsis	cancers, congenital disorders [97,99,100,101]
acquired chromosomal translocations	leukaemias [102] and lymphomas [103]
illegitimate immunoglobulin recombination	

positioned chiasmata are frequently observed, such that exchanges occurring too close to the centromere, as well as too far, are risk factors for non-disjunction [104–108].

Furthermore, aneuploidy rates increase with age in females. This 'maternal age effect' is particularly pronounced: under the age of 25, a woman has a 2% chance of having a trisomic pregnancy, but over the age of 40, this chance rises to 35%. This effect is thought to be due to age-related insults to the meiotic system at each stage of the oocyte development [109]. A number of studies have analysed different cohorts to determine if there is a similar age-related relationship with recombination [110–114], with either positive, negative or no relationship of chiasma number and age being observed. Nonetheless, the effect sizes and variance explained by age on chiasma frequency are either small or insignificant genome-wide, and recombination alone is unlikely to be responsible for maternal age effects on aneuploidies.

Aberrant gametogenesis leading to recurrent structural genetic abnormalities is a major cause of congenital birth defects. DSBs at sites of recombination will sometimes be aberrantly repaired with non-homologous loci, in a process called non-allelic homologous recombination (NAHR, table 1), which results in structural rearrangements. In most cases, rearrangements are flanked by low copy repeats that typically share sequence similarity greater than 98%. Generally, repeated DNA sequences play an important role in mediating disease-causing recombination errors. Pairing and homologous recombination between misaligned repetitive elements have been observed at rearrangement breakpoints related to disease and are thought to be the main mechanism of NAHR [89]. NAHR can result in chromosomal inversions and translocations or in local duplications and deletions. These rearrangements are likely to dramatically disrupt

genes, possibly creating fusion genes, and are for the most part deleterious. Genomic disorders associated with NAHR include: Charcot–Marie–Tooth disease type 1A, neurofibromatosis type 1, Williams–Beuren syndrome, Smith–Magenis syndrome, hereditary neuropathy with liability to pressure palsies, DiGeorge syndrome, Prader–Willi syndrome, childhood spinal muscular atrophy and the 17q21.31 microdeletion syndrome (table 1). Many of them result from megabase-scale duplications, as in Charcot–Marie–Tooth disease [115], or deletions, as in Smith–Magenis, Williams–Beuren, DiGeorge and Prader–Willi syndromes. Disease-causing and other NAHR breakpoints are not distributed evenly along the low copy repeats and cluster in narrow hotspots [116] that are often found at strikingly similar positions to those of hotspots resulting from allelic recombination [117,118]. Furthermore, NAHR hotspots and recombination hotspots share similar properties of distribution of strand exchange [118], suggesting that they are functionally related. Many lines of evidence also suggested that *PRDM9* variation correlates with instability in minisatellite repeats [38] and with recurrent pathological rearrangements, such as 17p11.2 deletions/duplication events [119] and 7q11.23 microdeletions [120]. Recurrent duplications or deletions at 17p11.2 are implicated in Charcot–Marie–Tooth disease and hereditary neuropathy with liability to pressure palsies, whereas 7q11.23 microdeletions cause Williams–Beuren syndrome. *PRDM9* thus appears to be involved in meiotic instabilities leading to genomic disorders.

There appears to be a sex-dependent component to some rearrangements, which do not arise at the same frequencies in paternal and maternal meioses. For example, the duplication or deletion at 17p11.2, associated with Charcot–Marie–Tooth disease or hereditary neuropathy with liability to pressure palsies, respectively, arises from two distinct sex-dependent

mechanisms [121]. Most de novo rearrangements are from paternal origin and arise by NAHR between the two chromosome 17 homologues, whereas the rare rearrangements of maternal origin result from an intra-chromosomal process. Interestingly, this region of chromosome 17 appears to have higher recombination rates in females than in males, suggesting that oogenesis may afford greater protection from misalignment during synapsis, or that male-specific factors may operate during spermatogenesis to help stabilize the rearrangements. Alternatively, sex-specific differences might reflect different selection bias against the rearranged alleles in male and female germ lines. Differences in NAHR frequency between male and female were also found at other loci, with childhood spinal muscular atrophy deletions originating mainly in spermatogenesis [122], whereas 80% of de novo neurofibromatosis type 1 deletions are of maternal origin [123].

(b) Mitotic homologous recombination and disease

Parallels appear to exist between meiotic recombination and tumorigenesis in somatic cells: in addition to the role of homologous recombination in promoting genomic stability by repairing DSBs in cells undergoing mitosis [124,125] and the overlapping molecular machinery involved [98,126,127], aberrant expression of proteins exclusively expressed in healthy adult testis, and associated with meiosis-specific functions, has recently been observed in tumours originating from non-germline tissues [128]. Moreover, PRDM9 and the inter-sister chromatid cohesion protein RAD21 L were found to be expressed in some cancer cell lines [129]. Owing to the meiotic recombination-specific functions of these proteins, it has been hypothesized that they might interfere with mitotic genome regulation [128].

Genome integrity in mitotic cells greatly relies on recombination, required for accurate repair of DSBs incurred either by exogenous (e.g. ultraviolet light) or endogenous processes (e.g. damage incurred during replication) during the life of the cell [130]. Owing to the essential role of mitotic recombination in genome integrity, the dysregulation of molecular mechanisms involved can often lead to diseases, including cancer (table 1). Research on the effect of mitotic recombination on the progression of tumorigenesis has largely focused on understanding the impact of loss of function mutations in tumour suppressor genes that are part of the homologous recombination repair (HRR) pathway, such as those included in the recognition of the DSB by the MRE11A-NBS1-RAD50 complex, the DNA resection guided by BRCA1 or the location of the recombinase RAD51 by BRCA2 [98,131,132]. The loss of function mutations in genes involved in the HRR pathway often lead to its inactivation, rendering DSB repair entirely dependent on the alternative non-homologous end-joining pathway. The non-homologous end-joining pathway does not involve homologous sequences as a template for repair, resulting in small insertions and deletions at the breakpoint locations [133] and therefore leaves a distinct mutational signature, characterized by increased genomic rearrangements and small indels, in tumours with HRR-pathway inactivation [134]. Capturing the genomic signature underlying the inactivation of the HRR pathway is important in cancer research, given the therapeutic success of poly(ADP-ribose) polymerase inhibitors that target HRR-pathway-deficient tumours [135,136]. By preventing genomic rearrangements through the accurate repair of highly damaging DSBs, mitotic recombination processes are

essential for ensuring genomic stability, although recombination processes may also be mutagenic when they go awry.

Mutagenic mitotic recombination events can mainly be identified through: (i) structural variation generated by NAHR or (ii) loss of heterozygosity (LOH) driven by biased gene conversion (figure 1). Structural variation detection algorithms can be used naively to detect NAHR events [141]. However, because NAHR often involves repetitive loci sharing a high homology, structural variation algorithms identify NAHR events with high error rates. Parks *et al.* [141] developed a Bayesian probabilistic model improving the detection of NAHR from sequencing data by focusing on regions prone to NAHR through their repetitive nature, which complements structural variation detection algorithms by enhancing their detection. Chromosomal microarray analysis of a cohort of 25 144 disease patients has recently catalogued NAHR-mediated copy number variants among numerous diseases (table 1) [90]. Furthermore, mitotic NAHR, found in a mosaic pattern across cells, appears to be associated with diseases involving genes with a large number of repeats such as the neurofibromin-1 loci [91] (table 1), further involving the mutagenicity of mitotic recombination to disease.

Mitotic-biased gene conversion is generally thought to be associated with tumorigenesis, as local LOH events are frequent among tumour genomes [142,143]. Notably, LOH of the wild-type allele of tumour suppressors is frequently and recurrently observed. The detection of LOH is possible through sequencing and identification of heterozygous loci in the germline genome that are homozygous in the tumour genome (figure 1c) [137]. Traditionally, LOH events were captured by detecting karyotypic changes [144], while newer methods leverage read counts from high throughput sequences [145] and SNP array information [143]. Mitotic-biased gene conversion events leading to LOH are identified once they have reached fixation in the tumour population due to their high selective advantage on tumour growth, whereas passenger alleles generated by mitotic-biased gene conversion with neutral effects will be much less likely to be found at high frequency across tumour cells. Some LOH events likely originated owing to general genome instability, making it challenging to distinguish which LOH events are associated with causing genomic instability, and which are a consequence of it. Nonetheless, LOH inference has been used to identify candidate cancer drivers, as it is likely that the loss of an allele throughout cancer clonal populations confers a selective advantage for cancer progression, such as the loss of function of wild-type alleles of MLH1/MSH2 [146].

Finally, some genomic regions are prone to mitotic recombination events, including *Alu* transposable elements, which are additionally found neighbouring leukaemia translocation events [147], suggesting a link of the mutagenic effect of mitotic recombination to leukaemogenesis [103].

4. Evolution and functional impact of sex and recombination

(a) Evolutionary advantages of recombination

Fisher [12] and Muller [13] proposed that sexual reproduction and recombination are evolutionarily advantageous as they accelerate the rate of fixation of beneficial mutations and thereby the rate of adaptation by bringing beneficial alleles




Figure 1. Gene conversion leading to LOH events in tumour cells. (a) A potential tumour cell that has incurred a LOH will increase in frequency as a subpopulation within a tissue or tumour. (b) A cell repairing a DSB mediated via a crossover or non-crossover, giving rise to two daughter cells exhibiting LOH. The examples shown correspond to a model in which the DSB repair pathway is followed by the resolution of a double Holliday junction, although other mechanisms may lead to gene conversion (as described in [137–139]). Mismatched bases may originate via DNA synthesis when the sister chromatid is used as a template for repair, resulting in a non-reciprocal exchange between both DNA strands [140]. LOH occurs during gene conversion when germline variants are heterozygous (as shown). If homologous recombination occurs during a two-homologue chromatid invasion, as is more often the case, only a non-crossover model leads to LOH, whereas with a four chromatid invasion, crossovers and non-crossovers lead to LOH only when recombinant chromatids segregate to the same daughter cell. (c) LOH events can be captured by counting the number of sequencing reads from tumour samples carrying the alternative alleles at heterozygous sites identified in germline (or healthy tissue). Nevertheless, challenges are associated with the detection of LOH events from sequencing data. Owing to cell mixture in the tumour, the signal for LOH events can be lost, and may not distinguishable from sequencing errors and mapping bias effects.

that arise initially on different genomic backgrounds together on the same chromosome. Later, when assuming that most mutations are deleterious, Muller proposed that in the absence of recombination, disadvantageous mutations accumulate in an irreversible manner such that a mutation-free state can never be recovered (reverse mutations are rare), the so-called Muller's ratchet effect [14]. These initial theoretical models were extended by the introduction of additional assumptions on the role of random drift, selection and linkage. Such developments led to the emergence of concepts like Hill–Robertson (HR) interference, which postulates that in the presence of drift and linkage, linked loci subject to selection will interfere with each other's allelic frequency trajectories over time [15,17]. Allele frequencies at one site will not only depend on drift and their evolutionary fitness but will also depend on the fitness of linked genotypes. The persistence of associations between loci generated by HR interference depends

on the recombination rate between them: the smaller the recombination rate, the longer these associations will last.

Selection on beneficial mutations drives target mutations to fixation, increasing LD and decreasing neutral diversity in linked surrounding regions (figure 2a), commonly referred to as selective sweeps. Positive selection was thought to be responsible for genetic diversity troughs and elevated population differentiation in or close to genic regions [149] as well as in regions of low recombination [150]. However, complete selective sweep signatures across the genome were found to be scarce [151] and instead, low levels of diversity in regions of low recombination are more likely to have been generated by background selection against deleterious mutations [152–154] (figure 2b). Under a scenario of positive selection and in the presence of HR interference [17,148,155], slightly deleterious mutations may reach high frequencies when neighbouring the target of positive selection (green diamond, figure 2a). In the




Figure 2. Schematic of HR interference under alternative selection regimes: (a) advantageous mutations arise on different backgrounds (haplotypes), interfere with each other and prevent each other's fixation. Linked neutral and slightly deleterious variants will increase in frequency until recombination generates new haplotypes, which drive beneficial mutations (now in the same haplotype) quickly to fixation while purging slightly deleterious alleles. (b) Deleterious alleles enter the population on different haplotypes. Owing to drift and/or to interference with selective advantageous mutations, they remain at low frequencies in the population until recombination generates a new haplotype resulting from the combination of the two deleterious alleles. Selection will remove this new haplotype more efficiently. However, an advantageous mutation will be lost, given that there was not enough time for recombination to break its association with a deleterious background. (c) Negative selection on multiple linked slightly deleterious mutations (referred to as a weak HR effect in Charlesworth *et al.* [148])—owing to the limited burden carried by such mutations, slightly deleterious variants tend to remain and accumulate in populations. Haplotypes that carry a larger mutational burden can be successively removed from the population. Interference occurs when there is little to no recombination, and selection at other loci on different haplotypes reduces the effective population size, impacting the rate at which they are lost from the population by making it more difficult to remove haplotypes that carry these deleterious mutations. Recombination combines chromosomes to create haplotypes that are free of or are loaded with deleterious mutations, increasing the efficacy of selection. Examples of mutations along the chromosomes (grey lines) are represented by different colours.

case of background selection with HR interference, advantageous mutations arising on a chromosome carrying several deleterious mutations will have a lower, if not null, chance of spreading in the population (grey star, figure 2*b*). Moreover, in the presence of HR interference, selection against slightly deleterious linked mutations will interfere with the elimination of neighbouring harmful alleles of small effect onto alternative haplotypes [156]. The impact of HR interference on the effectiveness of selection can be described as a process associated with a reduction in effective population size at a locus under selection and surrounding loci, reducing variation and selection efficacy. Recombination has the potential to elevate effective population size locally by recombining selected alleles onto other backgrounds, making natural selection more efficient.

(b) Impact of recombination on genomic diversity and mutation load in humans

Exome variation among human populations has revealed that humans carry a surprisingly large number of potentially

damaging or disease-causing mutations [157–159]. Understanding why mutational burden persists requires understanding the role of population demographic and recombination history in the accrual of deleterious mutations. Several studies have shown that smaller human populations harbour relatively more damaging functional variation, relative to the number of neutral variants, when compared with their larger progenitor populations [157,160,161]. Elevated mutational burden in small populations may be caused by either inbreeding or decreased effectiveness of selection in removing potentially damaging mutations. While studies disagree with respect to the existence of significant differences in total mutation load among populations with different demographic histories [162,163], none of the above studies evaluated the impact of genomic heterogeneity in recombination frequencies on mutation load. More recently, by comparing patterns of accumulation of putative damaging mutations across regions with low (coldspots) and high (hotspots) rates of recombination, Hussin *et al.* [164] showed that coding regions with low rates of crossing over harbour relatively larger amounts of

potentially damaging mutations than highly recombining regions, consistent with reduced efficacy of purifying selection in purging harmful variation in coldspots. Furthermore, the efficiency of purifying selection was found to lessen as the number of alleles being selected against on the same haplotype increases, consistent with HR interference, with this effect being amplified as the effective population size becomes smaller (figure 2c).

While recombination rates have been found to shape diversity along the human genome mainly by increasing the efficacy of natural selection [164–166], evidence exists for local impact of recombination on sequence evolution via GC-biased gene conversion [46,138,167,168]. GC-biased gene conversion results in the non-reciprocal transmission of genomic content during the recombination process and increases the transmission probability of GC alleles over AT. The biased transmission of GC alleles may ultimately cause the local fixation of GC alleles in hotspots [169], likely contributing to the human mutation load [138,170]. Although genome-wide GC-biased gene conversion is a relatively weak evolutionary force [166,171], this process may lead to an increase in disease burden when recessive derived alleles have a higher chance of transmission due to GC-biased gene conversion [171]. In addition, it has been suggested that GC-biased gene conversion has evolved to compensate for the mutational burden directly associated with high mutation rates caused by the deamination of methylated cytosines at recombination hotspots [172].

5. Conclusion and future perspectives

In the past decade, our understanding of meiosis and the molecular regulation of recombination has greatly improved [68,172]. We have learned that the genomic location of DSBs, which promote meiotic recombination initiation, is non-randomly distributed and controlled by genetic and epigenetic factors such as PRDM9 [7,8,10,43,173–175] and potential interactors [46,176,177]. While the processes catalysed by PRDM9 binding are important, it is equally critical that we characterize the molecular factors contributing to the initial recruitment of PRDM9 to its binding sites (see the review by Tiemann-Boege *et al.* in this issue [46]). Differences in the intensity of DSB hotspots are only partially explained by genetic variation at PRDM9 binding sites [44]. This suggests that not all potential PRDM9 binding sites will incur a DSB and initiate the process of recombination, with recent evidence for additional levels of regulation implicating KRAB-ZNF genes in meiotic recombination suppression [178]. Local chromatin state influences the binding of PRDM9, but it remains to be investigated how both wider sequence context and chromatin accessibility are associated with differences in the intensity of DSB hotspots in individuals carrying the same PRDM9 alleles. An intriguing hypothesis is that fertility may be influenced by the specific allele one carries, if it positively affects the expression of important meiotic genes, such as *CTCF* [178]. Furthermore, while some missense *PRDM9* mutations have been associated with infertility in human males [84,86], a loss of function variant of PRDM9 in a fertile human female has recently been observed [179], raising the possible existence of sexual dimorphism in recombination-associated infertility in our species. Together this suggests that in humans, PRDM9 might not be imperative for the correct functioning of

recombination processes, as compensatory factors may exist, at least in human females.

Despite such advances, key steps of the mammalian meiotic programme are weakly understood, because meiosis remains challenging to study due to the lack of appropriate *in vitro* models. For example, cytological techniques require fetal ovarian tissue or testicular biopsies, but more importantly, these methods cannot be used for high-resolution analyses of DSBs and crossovers (see [180] for exception). On the other hand, sperm genotyping assays, which rely on PCR amplification of DNA from single-sperm and pooled-sperm, can examine thousands of meioses from a single individual at resolutions of less than 0.5 kb [181], the trade-off being that it remains technically challenging to study genomic regions larger than 300 kb at high resolution.

More recently, novel techniques have been developed to facilitate genome-wide identification of epigenetic marks, sites of recombination and nucleosome organization in meiosis [41,46,181–184]. These approaches generally map DSB sites directly and while not directly mapping crossovers, DSB formation is the prelude to recombination. One of these assays, using chromatin immunoprecipitation followed by sequencing (ChIP-seq) and sensitive detection of single-stranded DNA, revealed that PRDM9 is not required for DSBs to occur in mice, but rather, moves them away from H3K4me3-marked promoter sites [185]. Furthermore, H3K36me3 and H3K4me3 ChIP-seq data in spermatocytes show that PRDM9 is able to place the two epigenetic marks on the same histone molecule *in vivo*, a signature that is exclusive to recombination hotspots [41]. Finally, a newly developed nucleotide-resolution technique, which sequences short oligonucleotides covalently bound to SPO11, provides detailed description of DSB hotspots, locating them among methylated nucleosomes, and has highlighted the importance of the ATM kinase in shaping sex-chromosome and the autosomal DSB landscape [186]. Application of these new techniques has so far been limited to studying male recombination, but new approaches are emerging to study female meiosis directly, and to provide precise information about meiosis in human oocytes. For example, it is now possible to generate genome-wide maps of crossovers and chromosome segregation patterns by recovering all three products of a single female meiosis, namely the two polar bodies and the activated oocyte, allowing the analysis of human tetrads [185,187,188]. Similarly, genomic analyses of single human oocytes using the polar bodies and recovering the female pronucleus from zygotes can be performed with multiple annealing and looping-based amplification cycle-based sequencing technology [189]. These technologies supported the generation of genome-wide oocytes' crossover maps and offer improved detection of chromosome abnormalities.

Finally, our understanding of the impact of GC-biased gene conversion, meiotic drive and recombination-related mutagenicity, beyond large-scale chromosomal rearrangements, on individual mutational burden may benefit considerably from single-cell sequencing by allowing the measurement of de novo mutations in the germline [189–191]. Single-cell sequencing of the gamete transcriptomes would specifically allow a better understanding of the repeat instability occurring in the PRDM9 ZnF coding sequence [192], and the rate at which new alleles of PRDM9 are generated. As the costs of single-cell sequencing technologies decrease, we will be able to dissect complex and heterogeneous gametocyte populations, which

will shed light on the extent to which individual-specific hotspots differ from the expected hotspot distribution and how these exceptions impact human health.

Data accessibility. This article has no additional data.

Competing interests. We have no competing interests.

Funding. A.A.H. is supported by an Ontario Graduate Scholarship. J.G.H. is an EPAC Junior Research Fellow at Linacre College, Oxford. I.A. and P.A. are supported by a Ministry of Research and Innovation (Ontario) Senior Investigator Award (Awadalla).

References

- Roach JC *et al.* 2010 Analysis of genetic inheritance in a family quartet by whole-genome sequencing. *Science* **328**, 636–639. (doi:10.1126/science.1186802)
- Awadalla P *et al.* 2010 Direct measure of the *de novo* mutation rate in autism and schizophrenia cohorts. *Am. J. Hum. Genet.* **87**, 316–324. (doi:10.1016/j.ajhg.2010.07.019)
- Conrad DF *et al.* 2011 Variation in genome-wide mutation rates within and between human families. *Nat. Genet.* **43**, 712–714. (doi:10.1038/ng.862)
- Kong A *et al.* 2012 Rate of *de novo* mutations and the importance of father's age to disease risk. *Nature* **488**, 471–475. (doi:10.1038/nature11396)
- The International HapMap Consortium. 2005 A haplotype map of the human genome. *Nature* **437**, 1299–1320. (doi:10.1038/nature04226)
- Frazer KA *et al.* 2007 A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861. (doi:10.1038/nature06258)
- McVean G, Myers SRR, Hunt S, Deloukas P, Bentley DRR, Donnelly P. 2004 The fine-scale structure of recombination rate variation in the human genome. *Science* **304**, 581–584. (doi:10.1126/science.1092500)
- Myers S, Bottolo L, Freeman C, McVean G, Donnelly P. 2005 A fine-scale map of recombination rates and hotspots across the human genome. *Science* **310**, 321–324. (doi:10.1126/science.1117196)
- Baudat F, Buard J, Grey C, Fledel-Alon A, Ober C, Przeworski M, Coop G, de Massy B. 2010 PRDM9 is a major determinant of meiotic recombination hotspots in humans and mice. *Science* **327**, 836–840. (doi:10.1126/science.1183439)
- Myers S, Bowden R, Tumian A, Bontrop REE, Freeman C, MacFie TSS, McVean G, Donnelly P. 2010 Drive against hotspot motifs in primates implicates the PRDM9 gene in meiotic recombination. *Science* **327**, 876–879. (doi:10.1126/science.1182363)
- Parvanov EDD, Petkov PMM, Paigen K. 2010 Prdm9 controls activation of mammalian recombination hotspots. *Science* **327**, 835. (doi:10.1126/science.1181495)
- Fisher RA. 1930 *The genetical theory of natural selection: a complete variorum edition*. Oxford, UK: Oxford University Press.
- Muller HHJ. 1932 Some genetic aspects of sex. *Am. Nat.* **66**, 118–138. (doi:10.1086/280418)
- Muller HJ. 1964 The relation of recombination to mutational advance. *Mutat. Res. Mol. Mech. Mutagen.* **1**, 2–9. (doi:10.1016/0027-5107(64)90047-8)
- Hill WG, Robertson A. 1966 The effect of linkage on limits to artificial selection. *Genet. Res.* **8**, 269–294. (doi:10.1017/S0016672300010156)
- Hill WG, Robertson A. 1968 Linkage disequilibrium in finite populations. *Theor. Appl. Genet.* **38**, 226–231. (doi:10.1007/BF01245622)
- Felsenstein J. 1974 The evolutionary advantage of recombination. *Genetics* **78**, 737–756.
- Baker BS, Carpenter ATC, Esposito MS, Esposito RE, Sandler L. 1976 The genetic control of meiosis. *Annu. Rev. Genet.* **10**, 53–134. (doi:10.1146/annurev.ge.10.120176.000413)
- Koehler KE, Hawley RS, Sherman S, Hassold T. 1996 Recombination and nondisjunction in humans and flies. *Hum. Mol. Genet.* **5**(Suppl. 1), 1495–1504. (doi:10.1093/hmg/5.Supplement_1.1495)
- Baudat F, de Massy B. 2007 Regulating double-stranded DNA break repair towards crossover or non-crossover during mammalian meiosis. *Chromosom. Res.* **15**, 565–577. (doi:10.1007/s10577-007-1140-3)
- Bernstein H, Byerly HC, Hopf FA, Michod RE. 1985 Genetic damage, mutation, and the evolution of sex. *Science* **229**, 1277–1281. (doi:10.1126/science.3898363)
- Bernstein H, Byers GS, Michod RE. 1981 Evolution of sexual reproduction: importance of DNA repair, complementation, and variation. *Am. Nat.* **117**, 537–549. (doi:10.1086/283734)
- Chakravarti A, Buetow KH, Antonarakis SE, Waber PG, Boehm CD, Kazazian HH. 1984 Nonuniform recombination within the human beta-globin gene cluster. *Am. J. Hum. Genet.* **36**, 1239–1258.
- Chakravarti A, Elbein SC, Permutt MA. 1986 Evidence for increased recombination near the human insulin gene: implication for disease association studies. *Proc. Natl Acad. Sci. USA* **83**, 1045–1049. (doi:10.1073/pnas.83.4.1045)
- Dib C *et al.* 1996 A comprehensive genetic map of the human genome based on 5,264 microsatellites. *Nature* **380**, 152–154. (doi:10.1038/380152a0)
- Murray JC *et al.* 1994 A comprehensive human linkage map with centimorgan density. Cooperative Human Linkage Center (CHLC). *Science* **265**, 2049–2054. (doi:10.1126/science.8091227)
- Broman KWW, Murray JCC, Sheffield VCC, White RLL, Weber JLL. 1998 Comprehensive human genetic maps: individual and sex-specific variation in recombination. *Am. J. Hum. Genet.* **63**, 861–869. (doi:10.1086/302011)
- Kong A *et al.* 2002 A high-resolution recombination map of the human genome. *Nat. Genet.* **31**, 241–247. (doi:10.1038/ng917)
- Jeffreys AJ, Ritchie A, Neumann R. 2000 High resolution analysis of haplotype diversity and meiotic crossover in the human TAP2 recombination hotspot. *Hum. Mol. Genet.* **9**, 725–733. (doi:10.1093/hmg/9.5.725)
- Jeffreys AJ, Kauppi L, Neumann R. 2001 Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. *Nat. Genet.* **29**, 217–222. (doi:10.1038/ng1001-217)
- May CA, Shone AC, Kalaydjieva L, Sajantila A, Jeffreys AJ. 2002 Crossover clustering and rapid decay of linkage disequilibrium in the Xp/Yp pseudoautosomal gene SHOX. *Nat. Genet.* **31**, 272–275. (doi:10.1038/ng918)
- Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. 2001 High-resolution haplotype structure in the human genome. *Nat. Genet.* **29**, 229–232. (doi:10.1038/ng1001-229)
- Wall JD. 2000 A comparison of estimators of the population recombination rate. *Mol. Biol. Evol.* **17**, 156–163. (doi:10.1093/oxfordjournals.molbev.a026228)
- Fearnhead P, Donnelly P. 2001 Estimating recombination rates from population genetic data. *Genetics* **159**, 1299–1318.
- McVean G, Awadalla P, Fearnhead P. 2002 A coalescent-based method for detecting and estimating recombination from gene sequences. *Genetics* **160**, 1231–1241.
- Auton A, McVean G. 2007 Recombination rate estimation in the presence of hotspots. *Genome Res.* **17**, 1219–1227. (doi:10.1101/gr.6386707)
- Li N, Stephens M. 2003 Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data. *Genetics* **165**, 2213–2233.
- Myers S, Freeman C, Auton A, Donnelly P, McVean G. 2008 A common sequence motif associated with recombination hot spots and genome instability in humans. *Nat. Genet.* **40**, 1124–1129. (doi:10.1038/ng.213)
- Berg IL, Neumann R, Sarbajna S, Odenthal-hesse L, Butler NJ, Jeffreys AJ. 2011 Variants of the protein PRDM9 differentially regulate a set of human meiotic recombination hotspots highly active in African populations. *Proc. Natl Acad. Sci. USA* **108**, 12378–12383. (doi:10.1073/pnas.1109531108)
- Buard J, Barthès P, Grey C, de Massy B. 2009 Distinct histone modifications define initiation and repair of meiotic recombination in the mouse. *EMBO J.* **28**, 2616–2624. (doi:10.1038/emboj.2009.207)
- Powers NR, Parvanov ED, Baker CL, Walker M, Petkov PM, Paigen K. 2016 The meiotic recombination activator PRDM9 trimethylates both H3K36 and H3K4 at recombination hotspots *in vivo*. *PLoS Genet.* **12**, e1006146. (doi:10.1371/journal.pgen.1006146)

42. Eram MS *et al.* 2014 Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein. *J. Biol. Chem.* **289**, 12 177–12 188. (doi:10.1074/jbc.M113.523183)
43. Hayashi K, Yoshida K, Matsui Y. 2005 A histone H3 methyltransferase controls epigenetic events required for meiotic prophase. *Nature* **438**, 374–378. (doi:10.1038/nature04112)
44. Pratto F, Brick K, Khil P, Smagulova F, Petukhova GV, Camerini-Otero RD. 2014 Recombination initiation maps of individual human genomes. *Science* **346**, 1256442. (doi:10.1126/science.1256442)
45. Jeffreys AJ, Neumann R, Panayi M, Myers S, Donnelly P. 2005 Human recombination hot spots hidden in regions of strong marker association. *Nat. Genet.* **37**, 601–606. (doi:10.1038/ng1565)
46. Tiemann-Boege I, Schwarz T, Striedner Y, Heissl A. 2017 The consequences of sequence erosion in the evolution of recombination hotspots. *Phil. Trans. R. Soc. B* **372**, 20160462. (doi:10.1098/rstb.2016.0462)
47. Ptak SE, Hinds DA, Koehler K, Nickel B, Patil N, Ballinger DG, Przeworski M, Frazer KA, Pääbo S. 2005 Fine-scale recombination patterns differ between chimpanzees and humans. *Nat. Genet.* **37**, 429–434. (doi:10.1038/ng1529)
48. Wall JD, Frisse LA, Hudson RR, Di Rienzo A. 2003 Comparative linkage-disequilibrium analysis of the β -Globin hotspot in primates. *Am. J. Hum. Genet.* **73**, 1330–1340. (doi:10.1086/380311)
49. Winckler W *et al.* 2005 Comparison of fine-scale recombination rates in humans and chimpanzees. *Science* **308**, 107–111. (doi:10.1126/science.1105322)
50. Auton A *et al.* 2012 A fine-scale chimpanzee genetic map from population sequencing. *Science* **336**, 193–198. (doi:10.1126/science.1216872)
51. Jeffreys AJ, Neumann R. 2002 Reciprocal crossover asymmetry and meiotic drive in a human recombination hot spot. *Nat. Genet.* **31**, 267–271. (doi:10.1038/ng910)
52. Coop G, Myers SR. 2007 Live hot, die young: transmission distortion in recombination hotspots. *PLoS Genet.* **3**, e35. (doi:10.1371/journal.pgen.0030035)
53. Oliver PLL *et al.* 2009 Accelerated evolution of the *Prdm9* speciation gene across diverse metazoan taxa. *PLoS Genet.* **5**, e1000753. (doi:10.1371/journal.pgen.1000753)
54. Boulton A, Myers RS, Redfield RJ. 1997 The hotspot conversion paradox and the evolution of meiotic recombination. *Proc. Natl Acad. Sci. USA* **94**, 8058–8063. (doi:10.1073/pnas.94.15.8058)
55. Lescage Y, Glémin S, Lartillot N, Mouchiroud D, Duret L. 2014 The red queen model of recombination hotspots evolution in the light of archaic and modern human genomes. *PLoS Genet.* **10**, e1004790. (doi:10.1371/journal.pgen.1004790)
56. Úbeda F, Wilkins JF. 2011 The Red Queen theory of recombination hotspots. *J. Evol. Biol.* **24**, 541–553. (doi:10.1111/j.1420-9101.2010.02187.x)
57. Baker CLL, Kajita S, Walker M, Saxl RLL, Raghupathy N, Choi K, Petkov PM, Paigen K. 2015 PRDM9 drives evolutionary erosion of hotspots in *Mus musculus* through haplotype-specific initiation of meiotic recombination. *PLoS Genet.* **11**, e1004916. (doi:10.1371/journal.pgen.1004916)
58. Singhal S *et al.* 2015 Stable recombination hotspots in birds. *Science* **350**, 928–932. (doi:10.1126/science.aad0843)
59. Auton A *et al.* 2013 Genetic recombination is targeted towards gene promoter regions in dogs. *PLoS Genet.* **9**, e1003984. (doi:10.1371/journal.pgen.1003984)
60. Mihola O, Trachtulec Z, Vlcek C, Schimenti JC, Forejt J. 2009 A mouse speciation gene encodes a meiotic histone H3 methyltransferase. *Science* **323**, 373–375. (doi:10.1126/science.1163601)
61. Flachs P *et al.* 2012 Interallelic and intergenic incompatibilities of the *Prdm9* (*Hst1*) gene in mouse hybrid sterility. *PLoS Genet.* **8**, e1003044. (doi:10.1371/journal.pgen.1003044)
62. Flachs P, Bhattacharyya T, Mihola O, Piálek J, Forejt J, Trachtulec Z. 2014 *Prdm9* incompatibility controls oligospermia and delayed fertility but no selfish transmission in mouse intersubspecific hybrids. *PLoS ONE* **9**, e95806. (doi:10.1371/journal.pone.0095806)
63. Davies B *et al.* 2016 Re-engineering the zinc fingers of PRDM9 reverses hybrid sterility in mice. *Nature* **530**, 171–176. (doi:10.1038/nature16931)
64. Larson EL, Keeble S, Vanderpool D, Dean MD, Good JM. 2017 The composite regulatory basis of the large x -effect in mouse speciation. *Mol. Biol. Evol.* **34**, 282–295. (doi:10.1093/molbev/msw243)
65. Handel MA, Schimenti JC. 2010 Genetics of mammalian meiosis: regulation, dynamics and impact on fertility. *Nat. Rev. Genet.* **11**, 124–136. (doi:10.1038/nrg2723)
66. Villeneuve AM, Hillers KJ. 2001 Whence meiosis? *Cell* **106**, 647–650. (doi:10.1016/S0092-8674(01)00500-1)
67. Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW. 1983 The double-strand-break repair model for recombination. *Cell* **33**, 25–35. (doi:10.1016/0092-8674(83)90331-8)
68. Zickler D, Kleckner N. 1999 Meiotic chromosomes: integrating structure and function. *Annu. Rev. Genet.* **33**, 603–754. (doi:10.1146/annurev.genet.33.1.603)
69. Rog O, Kohler S, Dernburg AF. 2017 The synaptonemal complex has liquid crystalline properties and spatially regulates meiotic recombination factors. *Elife* **6**, e21455. (doi:10.7554/eLife.21455)
70. Roeder GS, Bailis JM. 2000 The pachytene checkpoint. *Trends Genet.* **16**, 395–403. (doi:10.1016/S0168-9525(00)02080-1)
71. Revenkova E, Eijpe M, Heyting C, Hodges CA, Hunt PA, Liebe B, Scherthan H, Jessberger R. 2004 Cohesin SMC1 β is required for meiotic chromosome dynamics, sister chromatid cohesion and DNA recombination. *Nat. Cell Biol.* **6**, 555–562. (doi:10.1038/ncb1135)
72. Xu H, Beasley MD, Warren WD, van der Horst GTJ, McKay MJ. 2005 Absence of mouse REC8 cohesin promotes synapsis of sister chromatids in meiosis. *Dev. Cell* **8**, 949–961. (doi:10.1016/j.devcel.2005.03.018)
73. Yuan L, Liu JG, Zhao J, Brundell E, Daneholt B, Höög C. 2000 The murine *SCP3* gene is required for synaptonemal complex assembly, chromosome synapsis, and male fertility. *Mol. Cell* **5**, 73–83. (doi:10.1016/S1097-2765(00)80404-9)
74. Yang F, De La Fuente R, Leu NA, Baumann C, McLaughlin KJ, Wang PJ. 2006 Mouse SYCP2 is required for synaptonemal complex assembly and chromosomal synapsis during male meiosis. *J. Cell Biol.* **173**, 497–507. (doi:10.1083/jcb.200603063)
75. Bellani MA, Boateng KA, McLeod D, Camerini-Otero RD. 2010 The expression profile of the major mouse SP011 isoforms indicates that SP011 β introduces double strand breaks and suggests that SP011 α has an additional role in prophase in both spermatocytes and oocytes. *Mol. Cell Biol.* **30**, 4391–4403. (doi:10.1128/MCB.00002-10)
76. Kuznetsov S *et al.* 2007 RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. *J. Cell Biol.* **176**, 581–592. (doi:10.1083/jcb.200608130)
77. Coop G, Przeworski M. 2007 An evolutionary view of human recombination. *Nat. Rev. Genet.* **8**, 23–34. (doi:10.1038/nrg1947)
78. Donis-Keller H *et al.* 1987 A genetic linkage map of the human genome. *Cell* **51**, 319–337. (doi:10.1016/0092-8674(87)90158-9)
79. Kong A *et al.* 2010 Fine-scale recombination rate differences between sexes, populations and individuals. *Nature* **467**, 1099–1103. (doi:10.1038/nature09525)
80. Kong A *et al.* 2008 Sequence variants in the *RNF212* gene associate with genome-wide recombination rate. *Science* **319**, 1398–1401. (doi:10.1126/science.1152422)
81. Kong A *et al.* 2014 Common and low-frequency variants associated with genome-wide recombination rate. *Nat. Genet.* **46**, 11–16. (doi:10.1038/ng.2833)
82. Miyamoto T, Hasuike S, Yogev L, Maduro MR, Ishikawa M, Westphal H, Lamb DJ. 2003 Azoospermia in patients heterozygous for a mutation in *SYCP3*. *Lancet* **362**, 1714–1719. (doi:10.1016/S0140-6736(03)14845-3)
83. Christensen GL, Ivanov IP, Atkins JF, Mielnik A, Schlegel PN, Carrell DT. 2005 Screening the *SPO11* and *EIF5A2* genes in a population of infertile men. *Fertil. Steril.* **84**, 758–760. (doi:10.1016/j.fertnstert.2005.03.053)
84. Irie S, Tsujimura A, Miyagawa Y, Ueda T, Matsuoka Y, Matsui Y, Okuyama A, Nishimune Y, Tanaka H. 2009 Single-nucleotide polymorphisms of the *PRDM9* (*MEISETZ*) gene in patients with nonobstructive azoospermia. *J. Androl.* **30**, 426–431. (doi:10.2164/jandrol.108.006262)
85. Singh P, Schimenti JC. 2015 The genetics of human infertility by functional interrogation of SNPs in mice. *Proc. Natl Acad. Sci. USA* **112**, 10 431–10 436. (doi:10.1073/pnas.1506974112)
86. Miyamoto T, Koh E, Sakugawa N, Sato H, Hayashi H, Namiki M, Sengoku K. 2008 Two single nucleotide polymorphisms in *PRDM9* (*MEISETZ*) gene may be a

- genetic risk factor for Japanese patients with azoospermia by meiotic arrest. *J. Assist. Reprod. Genet.* **25**, 553–557. (doi:10.1007/s10815-008-9270-x)
87. Mouka A *et al.* 2017 Induced pluripotent stem cell generation from a man carrying a complex chromosomal rearrangement as a genetic model for infertility studies. *Sci. Rep.* **7**, 39760. (doi:10.1038/srep39760)
88. Hassold T, Hunt P. 2001 To err (meiotically) is human: the genesis of human aneuploidy. *Nat. Rev. Genet.* **2**, 280–291. (doi:10.1038/35066065)
89. Purandare SM, Patel PI. 1997 Recombination hot spots and human disease. *Genome Res.* **7**, 773–786. (doi:10.1101/gr.7.8.773)
90. Dittwald P *et al.* 2013 NAHR-mediated copy-number variants in a clinical population: mechanistic insights into both genomic disorders and Mendelizing traits. *Genome Res.* **23**, 1395–1409. (doi:10.1101/gr.152454.112)
91. Roehl AC *et al.* 2010 Intrachromosomal mitotic nonallelic homologous recombination is the major molecular mechanism underlying type-2 NF1 deletions. *Hum. Mutat.* **31**, 1163–1173. (doi:10.1002/humu.21340)
92. Gari K, Décaillot C, Stasiak AZ, Stasiak A, Constantinou A. 2008 The fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. *Mol. Cell.* **29**, 141–148. (doi:10.1016/j.molcel.2007.11.032)
93. Kutler DJ, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, Goberdhan A, Shah JP, Singh B. 2003 High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. *Arch. Otolaryngol. Neck Surg.* **129**, 106–112. (doi:10.1001/archotol.129.1.106)
94. Lieber MR, Hesse JE, Lewis S, Bosma GC, Rosenberg N, Mizuuchi K, Bosma MJ, Gellert M. 1988 The defect in murine severe combined immune deficiency: joining of signal sequences but not coding segments in V(DJ) recombination. *Cell* **55**, 7–16. (doi:10.1016/0092-8674(88)90004-9)
95. Cornsforth MN, Bedford JS. 1985 On the nature of a defect in cells from individuals with ataxia-telangiectasia. *Science* **227**, 1589–1592. (doi:10.1126/science.3975628)
96. Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates III JR, Hays L, Morgan WF, Petrini JHJ. 1998 The hMre11/hRad50 protein complex and nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. *Cell* **93**, 477–486. (doi:10.1016/S0092-8674(00)81175-7)
97. Wu L, Hickson ID. 2003 The Bloom's syndrome helicase suppresses crossing over during homologous recombination. *Nature* **426**, 870–874. (doi:10.1038/nature02253)
98. Moynahan ME, Jasin M. 2010 Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. *Nat. Rev. Mol. Cell Biol.* **11**, 196–207. (doi:10.1038/nrm2851)
99. Haffner MC *et al.* 2010 Androgen-induced TOP2B-mediated double strand breaks and prostate cancer gene rearrangements. *Nat. Genet.* **42**, 668–675. (doi:10.1038/ng.613)
100. Kloosterman WP *et al.* 2012 Constitutional chromothripsis rearrangements involve clustered double-stranded DNA breaks and nonhomologous repair mechanisms. *Cell Rep.* **1**, 648–655. (doi:10.1016/j.celrep.2012.05.009)
101. Zhang C-Z, Spektor A, Cornils H, Francis JM, Jackson EK, Liu S, Meyerson M, Pellman D. 2015 Chromothripsis from DNA damage in micronuclei. *Nature* **522**, 179–184. (doi:10.1038/nature14493)
102. Hussin J *et al.* 2013 Rare allelic forms of *PRDM9* associated with childhood leukemogenesis. *Genome Res.* **23**, 419–430. (doi:10.1101/gr.144188.112)
103. Rodić N, Zampella JG, Cornish TC, Wheelan SJ, Burns KH. 2013 Translocation junctions in *TCF3-PBX1* acute lymphoblastic leukemia/lymphoma cluster near transposable elements. *Mob. DNA* **4**, 22. (doi:10.1186/1759-8753-4-22)
104. Hassold T, Merrill M, Adkins K, Freeman S, Sherman S. 1995 Recombination and maternal age-dependent nondisjunction: molecular studies of trisomy 16. *Am. J. Hum. Genet.* **57**, 867–874.
105. Lamb NE *et al.* 1997 Characterization of susceptible chiasma configurations that increase the risk for maternal nondisjunction of chromosome 21. *Hum. Mol. Genet.* **6**, 1391–1399. (doi:10.1093/hmg/6.9.1391)
106. Thomas NS, Ennis S, Sharp AJ, Durkie M, Hassold TJ, Collins AR, Jacobs PA. 2001 Maternal sex chromosome non-disjunction: evidence for X chromosome-specific risk factors. *Hum. Mol. Genet.* **10**, 243–250. (doi:10.1093/hmg/10.3.243)
107. Bugge M *et al.* 1998 Non-disjunction of chromosome 18. *Hum. Mol. Genet.* **7**, 661–669. (doi:10.1093/hmg/7.4.661)
108. Robinson WP *et al.* 1998 Maternal meiosis I non-disjunction of chromosome 15: dependence of the maternal age effect on level of recombination. *Hum. Mol. Genet.* **7**, 1011–1019. (doi:10.1093/hmg/7.6.1011)
109. Hassold T, Hunt P. 2009 Maternal age and chromosomally abnormal pregnancies: what we know and what we wish we knew. *Curr. Opin. Pediatr.* **21**, 703–708. (doi:10.1097/MOP.0b013e328332c6ab)
110. Hussin J, Roy-Gagnon M-HH, Gendron R, Andelfinger G, Awadalla P. 2011 Age-dependent recombination rates in human pedigrees. *PLoS Genet.* **7**, e1002251. (doi:10.1371/journal.pgen.1002251)
111. Kong A *et al.* 2004 Recombination rate and reproductive success in humans. *Nat. Genet.* **36**, 1203–1206. (doi:10.1038/ng1445)
112. Bleazard T, Ju YS, Sung J, Seo JS. 2013 Fine-scale mapping of meiotic recombination in Asians. *BMC Genet.* **14**, 19. (doi:10.1186/1471-2156-14-19)
113. Martin HC *et al.* 2015 Multicohort analysis of the maternal age effect on recombination. *Nat. Commun.* **6**, 7846. (doi:10.1038/ncomms8846)
114. Campbell CL, Furlotte NA, Eriksson N, Hinds D, Auton A. 2015 Escape from crossover interference increases with maternal age. *Nat. Commun.* **6**, 6260. (doi:10.1038/ncomms7260)
115. Lupski JR *et al.* 1991 DNA duplication associated with Charcot-Marie-Tooth disease type 1A. *Cell* **66**, 219–232. (doi:10.1016/0092-8674(91)90613-4)
116. Lupski JR. 2004 Hotspots of homologous recombination in the human genome: not all homologous sequences are equal. *Genome Biol.* **5**, 242. (doi:10.1186/gb-2004-5-10-242)
117. Raedt TD *et al.* 2006 Conservation of hotspots for recombination in low-copy repeats associated with the *NF1* microdeletion. *Nat. Genet.* **38**, 1419–1423. (doi:10.1038/ng1920)
118. Lindsay SJ, Khajavi M, Lupski JR, Hurles ME. 2006 A chromosomal rearrangement hotspot can be identified from population genetic variation and is coincident with a hotspot for allelic recombination. *Am. J. Hum. Genet.* **79**, 890–902. (doi:10.1086/508709)
119. Berg IL, Neumann R, Lam K-WWG, Sarbajna S, Odenthal-Hesse L, May CA, Jeffreys AJ. 2010 *PRDM9* variation strongly influences recombination hot-spot activity and meiotic instability in humans. *Nat. Genet.* **42**, 859–863. (doi:10.1038/ng.658)
120. Borel C, Cheung F, Stewart H, Koolen DA, Phillips C, Thomas NS, Jacobs PA, Eliez S, Sharp AJ. 2012 Evaluation of *PRDM9* variation as a risk factor for recurrent genomic disorders and chromosomal non-disjunction. *Hum. Genet.* **131**, 1519–1524. (doi:10.1007/s00439-012-1180-4)
121. Lopes J *et al.* 1997 Sex-dependent rearrangements resulting in CMT1A and HNPP. *Nat. Genet.* **17**, 136–137. (doi:10.1038/ng1097-136)
122. Wirth B, Schmidt T, Hahnen E, Rudnik-Schoneborn S, Krawczak M, Muller-Myhsok B, Schönling J, Zerres K. 1997 De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. *Am. J. Hum. Genet.* **61**, 1102–1111. (doi:10.1086/301608)
123. Lazaro C, Gaona A, Ainsworth P, Tenconi R, Vidaur D, Krueyer H, Ars E, Volpini V, Estivill X. 1996 Sex differences in mutational rate and mutational mechanism in the *NF1* gene in neurofibromatosis type 1 patients. *Hum. Genet.* **98**, 696–699. (doi:10.1007/s004390050287)
124. Symington LS, Rothstein R, Lisby M. 2014 Mechanisms and regulation of mitotic recombination in *Saccharomyces cerevisiae*. *Genetics* **198**, 795–835. (doi:10.1534/genetics.114.166140)
125. Lisby M, Rothstein R. 2016 Cell biology of mitotic recombination. *Cold Spring Harb. Perspect. Biol.* **7**, 1–22. (doi:10.1101/cshperspect.a016535)
126. Shinohara A, Gasior S, Ogawa T, Kleckner N, Bishop DK. 1997 *Saccharomyces cerevisiae recA* homologues *RAD51* and *DMC1* have both distinct and overlapping roles in meiotic recombination. *Genes Cells* **2**, 615–629. (doi:10.1046/j.1365-2443.1997.1480347.x)
127. Klein HL. 1997 RDH54, a *RAD54* homologue in *Saccharomyces cerevisiae*, is required for mitotic diploid-specific recombination and repair and for meiosis. *Genetics* **147**, 1533–1543.

128. Sammut SJ, Feichtinger J, Stuart N, Wakeman JA, Larcombe L, McFarlane RJ. 2014 A novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets. *Oncoscience* **1**, 349–359. (doi:10.18632/oncoscience.37)
129. Feichtinger J *et al.* 2012 Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. *Oncotarget* **3**, 843–853. (doi:10.18632/oncotarget.580)
130. Mehta A, Haber JE. 2014 Sources of DNA double-strand breaks and models of recombinational DNA repair. *Cold Spring Harb. Perspect. Biol.* **6**, a016428. (doi:10.1101/cshperspect.a016428)
131. Krejčí L, Altmannova V, Spirek M, Zhao X. 2012 Homologous recombination and its regulation. *Nucleic Acids Res.* **40**, gks270. (doi:10.1093/nar/gks270)
132. Lord CJ, Ashworth A. 2016 BRCAness revisited. *Nat. Rev. Cancer* **16**, 110–120. (doi:10.1038/nrc.2015.21)
133. Jackson SPP. 2002 Sensing and repairing DNA double-strand breaks. *Carcinogenesis* **23**, 687–696. (doi:10.1093/carcin/23.5.687)
134. Alexandrov LB *et al.* 2013 Signatures of mutational processes in human cancer. *Nature* **500**, 415–421. (doi:10.1038/nature12477)
135. Ledermann JA, Drew Y, Kristeleit RS. 2016 Homologous recombination deficiency and ovarian cancer. *Eur. J. Cancer* **60**, 49–58. (doi:10.1016/j.ejca.2016.03.005)
136. Brown JS, Kaye SB, Yap TA. 2016 PARP inhibitors: the race is on. *Br. J. Cancer* **114**, 713–715. (doi:10.1038/bjc.2016.67)
137. Chen J-M, Cooper DN, Chuzhanova N, Férec C, Patrinos GP. 2007 Gene conversion: mechanisms, evolution and human disease. *Nat. Rev. Genet.* **8**, 762–775. (doi:10.1038/nrg2193)
138. Galtier N, Duret L, Glémin S, Ranwez V. 2009 GC-biased gene conversion promotes the fixation of deleterious amino acid changes in primates. *Trends Genet.* **25**, 1–5. (doi:10.1016/j.tig.2008.10.011)
139. Marais G. 2003 Biased gene conversion: implications for genome and sex evolution. *Trends Genet.* **19**, 330–338. (doi:10.1016/S0168-9525(03)00116-1)
140. Spies M, Fishel R. 2015 Mismatch repair during homologous and homeologous recombination. *Cold Spring Harb Perspect Biol.* **7**, a022657. (doi:10.1101/cshperspect.a022657)
141. Parks MM, Lawrence CE, Raphael BJ. 2015 Detecting non-allelic homologous recombination from high-throughput sequencing data. *Genome Biol.* **16**, 72. (doi:10.1186/s13059-015-0633-1)
142. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. 1983 Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. *Nature* **305**, 779–784. (doi:10.1038/305779a0)
143. Ryland GL *et al.* 2015 Loss of heterozygosity: what is it good for? *BMC Med. Genomics* **8**, 45. (doi:10.1186/s12920-015-0123-z)
144. Thiagalingam S, Laken S, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B, Lengauer C. 2001 Mechanisms underlying losses of heterozygosity in human colorectal cancers. *Proc. Natl Acad. Sci. USA* **98**, 2698–2702. (doi:10.1073/pnas.051625398)
145. Li H, Yang B, Xing K, Yuan N, Wang B, Chen Z, He W, Zhou J. 2014 A preliminary study of the relationship between breast cancer metastasis and loss of heterozygosity by using exome sequencing. *Sci. Rep.* **4**, 5460. (doi:10.1038/srep05460)
146. Zhang J, Lindroos A, Ollila S, Russell A, Marra G, Mueller H, Peltomaki P, Plasilova M, Heinimann K. 2006 Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from *MLH1/MSH2* deletion carriers. *Cancer Res.* **66**, 659–664. (doi:10.1158/0008-5472.CAN-05-4043)
147. Morales ME *et al.* 2015 The contribution of *Alu Elements* to mutagenic DNA double-strand break repair. *PLoS Genet.* **11**, e1005016. (doi:10.1371/journal.pgen.1005016)
148. Charlesworth B, Betancourt AJ, Kaiser VB, Gordo I. 2009 Genetic recombination and molecular evolution. *Cold Spring Harb. Symp. Quant. Biol.* **74**, 177–186. (doi:10.1101/sqb.2009.74.015)
149. Barreiro LB, Laval G, Quach H, Patin E, Quintana-Murci L. 2008 Natural selection has driven population differentiation in modern humans. *Nat. Genet.* **40**, 340–345. (doi:10.1038/ng.78)
150. Keinan A, Reich D. 2010 Human population differentiation is strongly correlated with local recombination rate. *PLoS Genet.* **6**, e1000886. (doi:10.1371/journal.pgen.1000886)
151. Hernandez RD, Kelley JL, Elyashiv E, Melton SC, Auton A, McVean G, Sella G, Przeworski M. 2011 Classic selective sweeps were rare in recent human evolution. *Science* **331**, 920–924. (doi:10.1126/science.1198878)
152. Charlesworth B, Morgan MT, Charlesworth D. 1993 The effect of deleterious mutations on neutral molecular variation. *Genetics* **134**, 1289–1303.
153. Hu X-S, He F. 2005 Background selection and population differentiation. *J. Theor. Biol.* **235**, 207–219. (doi:10.1016/j.jtbi.2005.01.004)
154. Charlesworth B. 2012 The effects of deleterious mutations on evolution at linked sites. *Genetics* **190**, 5–22. (doi:10.1534/genetics.111.134288)
155. Hartfield M, Keightley PD. 2012 Current hypotheses for the evolution of sex and recombination. *Integr. Zool.* **7**, 192–209. (doi:10.1111/j.1749-4877.2012.00284.x)
156. Keightley PD, Otto SP. 2006 Interference among deleterious mutations favours sex and recombination in finite populations. *Nature* **443**, 89–92. (doi:10.1038/nature05049)
157. Fu W *et al.* 2013 Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature* **493**, 216–220. (doi:10.1038/nature11690)
158. Tennessen JA *et al.* 2012 Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science* **337**, 64–69. (doi:10.1126/science.1219240)
159. Tabor HK *et al.* 2014 Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. *Am. J. Hum. Genet.* **95**, 183–193. (doi:10.1016/j.ajhg.2014.07.006)
160. Casals F *et al.* 2013 Whole-exome sequencing reveals a rapid change in the frequency of rare functional variants in a founding population of humans. *PLoS Genet.* **9**, e1003815. (doi:10.1371/journal.pgen.1003815)
161. Lohmueller KE *et al.* 2008 Proportionally more deleterious genetic variation in European than in African populations. *Nature* **451**, 994–997. (doi:10.1038/nature06611)
162. Do R, Balick D, Li H, Adzhubei I, Sunyaev S, Reich D. 2015 No evidence that selection has been less effective at removing deleterious mutations in Europeans than in Africans. *Nat. Genet.* **47**, 126–131. (doi:10.1038/ng.3186)
163. Simons YB, Turchin MC, Pritchard JK, Sella G. 2014 The deleterious mutation load is insensitive to recent population history. *Nat. Genet.* **46**, 220–224. (doi:10.1038/ng.2896)
164. Hussin JG, Hodgkinson A, Idaghmour Y, Grenier J-C, Goulet J-P, Gbeha E, Hip-Ki E, Awadalla P. 2015 Recombination affects accumulation of damaging and disease-associated mutations in human populations. *Nat. Genet.* **47**, 400–404. (doi:10.1038/ng.3216)
165. Nachman MW. 2001 Single nucleotide polymorphisms and recombination rate in humans. *Trends Genet.* **17**, 481–485. (doi:10.1016/S0168-9525(01)02409-X)
166. Yu A *et al.* 2001 Comparison of human genetic and sequence-based physical maps. *Nature* **409**, 951–953. (doi:10.1038/35057185)
167. Galtier N, Piganeau G, Mouchiroud D, Duret L. 2001 GC-content evolution in mammalian genomes: the biased gene conversion hypothesis. *Genetics* **159**, 907–911.
168. Glémin S, Arndt PF, Messer PW, Petrov D, Galtier N, Duret L. 2015 Quantification of GC-biased gene conversion in the human genome. *Genome Res.* **25**, 1215–1228. (doi:10.1101/gr.185488.114)
169. Duret L, Arndt PF. 2008 The impact of recombination on nucleotide substitutions in the human genome. *PLoS Genet.* **4**, e1000071. (doi:10.1371/journal.pgen.1000071)
170. Webster MT, Hurst LD. 2012 Direct and indirect consequences of meiotic recombination: implications for genome evolution. *Trends Genet.* **28**, 101–109. (doi:10.1016/j.tig.2011.11.002)
171. Lachance J, Tishkoff SA. 2014 Biased gene conversion skews allele frequencies in human populations, increasing the disease burden of recessive alleles. *Am. J. Hum. Genet.* **95**, 408–420. (doi:10.1016/j.ajhg.2014.09.008)
172. Arbeithuber B, Betancourt AJ, Ebner T, Tiemann-Boege I. 2015 Crossovers are associated with mutation and biased gene conversion at recombination hotspots. *Proc. Natl Acad. Sci. USA* **112**, 2109–2114. (doi:10.1073/pnas.1416622112)
173. Baudat F, Imai Y, de Massy B. 2013 Meiotic recombination in mammals: localization and regulation. *Nat. Rev. Genet.* **14**, 794–806. (doi:10.1038/nrg3573)

174. Billings T, Parvanov EDED, Baker CLCL, Walker M, Paigen K, Petkov PMPM. 2013 DNA binding specificities of the long zinc-finger recombination protein PRDM9. *Genome Biol.* **14**, R35. (doi:10.1186/gb-2013-14-4-r35)
175. Baker CLCL, Petkova P, Walker M, Flachs P, Mihola O, Trachtulec Z, Petkov PM, Paigen K. 2015 Multimer formation explains allelic suppression of PRDM9 recombination hotspots. *PLoS Genet.* **11**, e1005512. (doi:10.1371/journal.pgen.1005512)
176. Striedner Y, Schwarz T, Welte T, Futschik A, Rant U, Tiemann-Boege I. 2017 The long zinc finger domain of PRDM9 forms a highly stable and long-lived complex with its DNA recognition sequence. *Chromosome Res.* **25**, 155–172. (doi:10.1007/s10577-017-9552-1)
177. Parvanov ED, Tian H, Billings T, Saxl RL, Spruce C, Aithal R, Krejci L, Paigen K, Petkov PM. 2016 PRDM9 interactions with other proteins provide a link between recombination hotspots and the chromosomal axis in meiosis. *Mol. Biol. Cell* **28**, 488–499. (doi:10.1091/mbc.E16-09-0686)
178. Altemose N, Noor N, Bitoun E, Tumian A, Imbeault M, Chapman JR, Aricescu AR, Myers SR. 2017 Human PRDM9 can bind and activate promoters, and other zinc-finger proteins associate with reduced recombination in *cis*. bioRxiv 144295. (doi:10.1101/144295)
179. Narasimhan VM *et al.* 2016 Health and population effects of rare gene knockouts in adult humans with related parents. *Science* **352**, 474–477. (doi:10.1126/science.aac8624)
180. Prakash K *et al.* 2015 Superresolution imaging reveals structurally distinct periodic patterns of chromatin along pachytene chromosomes. *Proc. Natl Acad. Sci. USA* **112**, 14 635–14 640. (doi:10.1073/pnas.1516928112)
181. Kauppi L, Jeffreys AJ, Keeney S. 2004 Where the crossovers are: recombination distributions in mammals. *Nat. Rev. Genet.* **5**, 413–424. (doi:10.1038/nrg1346)
182. Khil PP, Smagulova F, Brick KM, Camerini-Otero RD, Petukhova GV. 2012 Sensitive mapping of recombination hotspots using sequencing-based detection of ssDNA. *Genome Res.* **22**, 957–965. (doi:10.1101/gr.130583.111)
183. Baker CL, Walker M, Kajita S, Petkov PM, Paigen K. 2014 PRDM9 binding organizes hotspot nucleosomes and limits Holliday junction migration. *Genome Res.* **24**, 724–732. (doi:10.1101/gr.170167.113)
184. Walker M *et al.* 2015 Affinity-seq detects genome-wide PRDM9 binding sites and reveals the impact of prior chromatin modifications on mammalian recombination hotspot usage. *Epigenet. Chromatin* **8**, 31. (doi:10.1186/s13072-015-0024-6)
185. Brick K, Smagulova F, Khil P, Camerini-Otero RD, Petukhova GV. 2012 Genetic recombination is directed away from functional genomic elements in mice. *Nature* **485**, 642–645. (doi:10.1038/nature11089)
186. Lange J, Yamada S, Tischfield SE, Pan J, Kim S, Zhu X, Socci ND, Jasin M, Keeney S. 2016 The landscape of mouse meiotic double-strand break formation, processing, and repair. *Cell* **167**, 695–708.e16. (doi:10.1016/j.cell.2016.09.035)
187. Handyside AH, Harton GL, Mariani B, Thornhill AR, Affara N, Shaw M-A, Griffin DK. 2010 Karyomapping: a universal method for genome wide analysis of genetic disease based on mapping crossovers between parental haplotypes. *J. Med. Genet.* **47**, 651–658. (doi:10.1136/jmg.2009.069971)
188. Ottolini CS *et al.* 2014 Genome-wide maps of recombination and chromosome segregation in human oocytes and embryos show selection for maternal recombination rates. *Nat. Genet.* **47**, 727–735. (doi:10.1038/ng.3306)
189. Hou Y *et al.* 2013 Genome analyses of single human oocytes. *Cell* **155**, 1492–1506. (doi:10.1016/j.cell.2013.11.040)
190. Ottolini CS, Capalbo A, Newnham L, Cimadomo D, Natesan SA, Hoffmann ER, Ubaldi FM, Rienzi L, Handyside AH. 2016 Generation of meiomaps of genome-wide recombination and chromosome segregation in human oocytes. *Nat. Protoc.* **11**, 1229–1243. (doi:10.1038/nprot.2016.075)
191. Wang J, Fan HC, Behr B, Quake SR. 2012 Genome-wide single-cell analysis of recombination activity and de novo mutation rates in human sperm. *Cell* **150**, 402–412. (doi:10.1016/j.cell.2012.06.030)
192. Jeffreys AJ, Cotton VE, Neumann R, Lam KG. 2013 Recombination regulator PRDM9 influences the instability of its own coding sequence in humans. *Proc. Natl Acad. Sci. USA* **110**, 600–605. (doi:10.1073/pnas.1220813110)